Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech biotechnology Cancer drug development Drug prices

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news roundup to start your week - 10 days ago The biotech news you need to read today - 18 days ago Element Biosciences raises another massive round - 4 months ago The biotech news you missed this week - 4 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago How resurrecting extinct species might impact medicine - 7 months ago Lawmakers want to add more Chinese biotechs to defense list - 8 months ago The Senate health committee looks into its first subpoena in 40 years - 10 months ago The biotech updates you need to read today - 11 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 11 months ago FDA chastens pet companies over antibiotics - 11 months ago The biotech news you missed from the weekend - 11 months ago CRISPR is about to make history. Here’s the 5-minute rundown of what to expect - 11 months ago Novartis is building a new radioligand plant in China - 12 months ago Today’s biotech news roundup, in under 800 words - 12 months ago A new algorithm unveils CRISPR ‘treasure trove’ - 12 months ago These are the need-to-know biotech stories from this weekend - about 1 year ago XBI biotech index rises, giving investors a shred of hope - about 1 year ago Shrinking Covid vaccine sales has Moderna course-correcting - about 1 year ago Your Monday morning biotech news roundup - about 1 year ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - about 1 year ago Want a biotech buyout? Target cancer - about 1 year ago
2	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	The biotech updates you need to read this morning - 25 days ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - about 1 month ago Who’s winning in biotech’s tight market? - 2 months ago Astellas’ science chief on the leap into new technologies - 9 months ago PharmaVoice 100s: Entrepreneurs - about 1 year ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - about 1 year ago
4	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	BioMarin’s big day today - 2 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 6 months ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 4 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 8 months ago STAT+: Biotech incubator Curie.Bio graduates its first startup - about 1 year ago STAT+: Life science investors close nearly $6 billion in new funds - about 1 year ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 5 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 7 months ago STAT+: Weed for weight loss, and more from Biotech Land - 7 months ago
7	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	The Best Biotech Stock to Invest $1,000 in Right Now - 5 months ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 6 months ago 4 offbeat biotechs making a splash in the life sciences - 7 months ago What’s old is new: The revival of a one-time radiotherapy cancer treatment - 7 months ago These biotech hotspots are ripe for IPOs - 8 months ago Black Diamond looks to outwit cancer mutations - 9 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Gas prices are hurting biotech - 7 months ago When did Wall Street sour on Lilly’s Alzheimer’s drug? - 8 months ago Another step toward new drugs for Parkinson’s - 10 months ago The XBI comedown after JPM - 10 months ago Why CG Oncology will be the first test of 2024’s IPO waters - 11 months ago The clock is ticking, and Cytokinetics is running out of December - 11 months ago BioMarin appeases an activist - 11 months ago STAT+: 3 trends to watch in biotech in 2024 - 11 months ago Is it time to worry about Moderna? - 11 months ago A plot to solve the ‘whack-a-mole’ of drug discovery - 11 months ago Tome Biosciences goes public today in another biotech megaround - 11 months ago Carmot’s chance of beating the odds in the biotech market just ended - 12 months ago Flagship Pioneering crosses the pond, opens a European front - 12 months ago Medtronic isn’t afraid of Wegovy’s potential to disrupt - 12 months ago Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead - 12 months ago The return of biotech’s “bump factor” amid an economic downturn - 12 months ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - about 1 year ago BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge - about 1 year ago Gene editing has had a big week in the spotlight. Here’s what’s going on - about 1 year ago What if there’s no market for a CRISPR cure? - about 1 year ago Cell and gene therapies could be a safer bet than other drugs - about 1 year ago
10	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - 8 months ago

Journalists covering Biotech Spotlight